Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer
Baishen Zhang,Jing Chen,Hui Yu,Meichen Li,Muyan Cai,Likun Chen
DOI: https://doi.org/10.2147/jir.s450804
IF: 4.5
2024-03-18
Journal of Inflammation Research
Abstract:Baishen Zhang, 1 Jing Chen, 2 Hui Yu, 2 Meichen Li, 2 Muyan Cai, 3 Likun Chen 2 1 Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China; 2 Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China; 3 Department of Pathology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China Correspondence: Muyan Cai, Department of Pathology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, 651 Dongfeng E Road, Yuexiu District, Guangzhou, 510060, People's Republic of China, Email Likun Chen, Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, 651 Dongfeng E Road, Yuexiu District, Guangzhou, 510060, People's Republic of China, Email Background: Currently, there is a lack of well-established markers to predict the efficacy of chemoimmunotherapy in small-cell lung cancer (SCLC). Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), advanced lung cancer inflammation index (ALI) and prognostic nutritional index (PNI) are associated with prognosis in several tumors, whereas their predictive role in SCLC remains unclear. Methods: A retrospective study was conducted at Sun Yat-sen University Cancer Center, involving extensive-stage SCLC (ES-SCLC) patients who received first-line chemoimmunotherapy between January 2020 and December 2021. Peripheral blood biomarkers were extracted from medical records and their correlation with prognosis and immune-related adverse events (IRAEs) was analyzed. Results: A total of 114 patients were included. Patients with a low PLR, high ALI and high PNI had prolonged progression-free survival (PFS) compared to those with a high PLR, low ALI and low PNI. Patients with a low NLR, low PLR, high ALI and high PNI had prolonged overall survival (OS) compared to those with a high NLR, high PLR, low ALI and low PNI. Cox regression model showed that PNI was an independent risk factor for both PFS and OS. ROC curve showed that PNI outperforms NLR, PLR and ALI in predicting both PFS and OS. The PNI-based nomogram demonstrated strong predictive capability for both PFS and OS. In addition, there was a significant correlation between PNI and IRAEs. Conclusion: A high baseline PNI might be associated with improved prognosis and the occurrence of IRAEs in ES-SCLC patients treated with first-line chemoimmunotherapy. Keywords: peripheral blood markers, predictive ability, chemoimmunotherapy, small-cell lung cancer, immune-related adverse events Lung cancer is a highly prevalent and lethal malignancy worldwide. Among its histological subtypes, small-cell lung cancer (SCLC) accounts for approximately 14% of all lung cancer cases. 1 SCLC is characterized by its remarkable aggressiveness, rapid growth and propensity for metastasis, and a majority of patients already have local or distant metastases at diagnosis. 2 For extensive-stage small-cell lung cancer (ES-SCLC) patients, systemic therapy plays a pivotal role in treatment, and platinum-based combination chemotherapy has been regarded as the standard approach over the past three decades. 3,4 However, its overall efficacy is modest, with a median overall survival (mOS) ranging from 8 to 13 months. 5,6 In recent years, there has been a growing trend in using immunotherapy in the treatment of ES-SCLC. 7 A clinical trial conducted on SCLC patients, IMpower133, 8 found that combining chemotherapy with immunotherapy (atezolizumab) significantly improved mOS compared with chemotherapy alone (12.3 months vs 10.3 months, HR = 0.70, 95% CI 0.54 to 0.91; P =0.007). Another clinical trial on SCLC, CASPIAN, 9 also showed that adding immunotherapy (durvalumab) to chemotherapy significantly improved mOS (13 months vs 10.3 months, HR = 0.73, 95% CI 0.59 to 0.91; p =0.0047). Therefore, chemotherapy plus immunotherapy has become a better first-line treatment option for ES-SCLC. 10 However, the efficacy benefit of adding immune checkpoint inhibitors to chemotherapy is still not satisfactory in ES-SCLC, and it may lead to various immune-related adverse events (IRAEs) in som -Abstract Truncated-
immunology